Aclaris Therapeutics (ACRS) Metrics: History & Chart

Aclaris Therapeutics, Inc.(ACRS)

Biotechnology · Wayne, PA

$3.80-0.47 (-11.12%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

Wayne, PA

71 employees

www.aclaristx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Neal S. Walker

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-21.36%
30D Total Return	-30.79%
YTD Total Return	+41.86%
1Y Total Return	+129.57%
3Y Total Return	-27.88%
5Y Total Return	-75.02%
10Y Total Return	-82.98%
15Y Total Return	N/A
20Y Total Return	N/A

2026	+41.86%
2025	+21.37%
2024	+136.19%
2023	-93.33%
2022	+8.32%
2021	+124.73%
2020

CAGR TTM	+128.66%
CAGR 3Y	-10.32%
CAGR 5Y	-24.23%
CAGR 10Y	-16.23%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

ACRS Valuation Metrics

ACRS Stock Price Metrics

ACRS Dividend Metrics

ACRS Growth Rate Metrics

ACRS Discounted Cash Flow Metrics

ACRS Returns By Period

ACRS Yearly Returns

ACRS Average Annual Returns By Period (CAGR)

ACRS Revenue Metrics

ACRS PE Ratio Metrics

ACRS PS Ratio Metrics

ACRS PB Ratio Metrics

ACRS Price to Free Cash Flow Ratio Metrics

ACRS Debt to Equity Ratio Metrics

ACRS PEG Ratio Metrics

ACRS FCF Yield

ACRS Earnings Yield

ACRS EBITDA Yield

ACRS OCF Yield

ACRS EV/EBIT Ratio Metrics

ACRS EV/EBITDA Ratio Metrics

ACRS EV/Assets Ratio Metrics

ACRS EV/Sales Ratio Metrics

ACRS Current Ratio Metrics

ACRS Quick Ratio Metrics

ACRS ROIC Metrics

ACRS Return on Assets Metrics

ACRS Return on Equity Metrics

ACRS Net Profit Margin Metrics

ACRS Gross Profit Margin Metrics

ACRS Tax Rate Metrics

PS Ratio	74.16
PS Ratio Avg TTM	55.76
PS Ratio Avg 3Y	9.54
Current VS TTM Avg	+33.00%
Current VS 3Y Avg	+677.21%
Current VS 5Y Avg	+49.60%

PB Ratio	4.89
PB Ratio Avg TTM	4.21
PB Ratio Avg 3Y	1.98
Current VS TTM Avg	+16.21%
Current VS 3Y Avg	+146.40%
Current VS 5Y Avg	+69.96%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.00
Debt/Equity Ratio Avg TTM	0.01
Debt/Equity Ratio Avg 3Y	0.01
Current VS TTM Avg	-100.00%
Current VS 3Y Avg	-100.00%
Current VS 5Y Avg	-100.00%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	3.29
Ev/Assets Ratio Avg TTM	2.77
Ev/Assets Ratio Avg 3Y	1.21
Current VS TTM Avg	+18.62%
Current VS 3Y Avg	+171.59%
Current VS 5Y Avg	+62.66%

Ev/Sales Ratio	71.82
Ev/Sales Ratio Avg TTM	53.58
Ev/Sales Ratio Avg 3Y	8.40
Current VS TTM Avg	+34.05%
Current VS 3Y Avg	+755.46%
Current VS 5Y Avg	+54.33%

Current Ratio	3.46
Current Ratio Avg TTM	4.12
Current Ratio Avg 3Y	5.03
Current VS TTM Avg	-15.90%
Current VS 3Y Avg	-31.17%
Current VS 5Y Avg	-55.42%

Quick Ratio	3.46
Quick Ratio Avg TTM	4.12
Quick Ratio Avg 3Y	5.03
Current VS TTM Avg	-15.90%
Current VS 3Y Avg	-31.17%
Current VS 5Y Avg	-55.42%

ROIC	(56.99%)
ROIC Avg 3Y	(62.62%)
ROIC Avg 5Y	(47.89%)
Current VS 3Y Avg	+9.00%
Current VS 5Y Avg	-18.99%
Current VS 10Y Avg	+1.94%

ROA	(42.15%)
ROA Avg TTM	(10.15%)
ROA Avg 3Y	(8.82%)
Current VS TTM Avg	-315.17%
Current VS 3Y Avg	-378.10%
Current VS 5Y Avg	-380.48%

ROE	(60.79%)
ROE Avg TTM	(78.49%)
ROE Avg 3Y	(67.89%)
Current VS TTM Avg	+22.55%
Current VS 3Y Avg	+10.46%
Current VS 5Y Avg	-16.41%

Net Profit Margin	(921.50%)
Net Profit Margin Avg TTM	(1030.63%)
Net Profit Margin Avg 3Y	(801.70%)
Current VS TTM Avg	+10.59%
Current VS 3Y Avg	-14.94%
Current VS 5Y Avg	-5.04%

Gross Profit Margin	73.28%
Gross Pft Margin Avg TTM	81.52%
Gross Pft Margin Avg 3Y	50.82%
Current VS TTM Avg	-10.11%
Current VS 3Y Avg	+44.19%
Current VS 5Y Avg	+83.07%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.10%
Tax Rate Avg 5Y	0.13%
Current VS 3Y Avg	-100.00%
Current VS 5Y Avg	-100.00%
Current VS 10Y Avg	-100.00%